Tuesday 9/17 Insider Buying Report: INBX, RPHM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 17 2024
0mins
Source: NASDAQ.COM
Inhibrx Biosciences Insider Purchase: CEO Mark Lappe purchased 40,000 shares of INBX for $629,117 at $15.73 each, experiencing a 13.1% gain as the stock peaked at $17.79 during trading on Tuesday.
Reneo Pharmaceuticals Insider Purchase: Braden Michael Leonard bought 358,923 shares of RPHM for $484,344 at $1.35 each, marking his third purchase in the past year, with the stock up about 1.5% on Tuesday.
Analyst Views on INBX
About INBX
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Its clinical pipeline of therapeutic candidates includes ozekibart (INBRX-109) and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that it designed with its proprietary single domain antibody (sdAb) platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist which is being investigated as a single agent and in combination with KEYTRUDA (pembrolizumab), a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
